Gastroenterology
Volume 138, Issue 2 , Pages 522-530 , February 2010

Screening and Early Treatment of Migrants for Chronic Hepatitis B Virus Infection Is Cost-Effective

  • Irene K. Veldhuijzen

      Affiliations

    • Division of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond, Rotterdam, The Netherlands
    • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    • Corresponding Author InformationReprint requests Address requests for reprints to: Irene K. Veldhuijzen, MD, Division of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond, PO Box 70032, 3000 LP Rotterdam, The Netherlands. fax: (31) 10-433 9747
    • ,
  • Mehlika Toy

      Affiliations

    • Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    • LiverDoc, Rotterdam, The Netherlands
    • ,
  • Susan J.M. Hahné

      Affiliations

    • National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands
    • ,
  • G. Ardine De Wit

      Affiliations

    • National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands
    • Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands
    • ,
  • Solko W. Schalm

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    • LiverDoc, Rotterdam, The Netherlands
    • ,
  • Robert A. de Man

      Affiliations

    • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    • ,
  • Jan Hendrik Richardus

      Affiliations

    • Division of Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond, Rotterdam, The Netherlands
    • Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

Received 2 July 2009 ,Accepted 19 October 2009.

References 

  1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107
  2. Goldstein ST, Zhou F, Hadler SC, et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34:1329–1339
  3. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008;26:6266–6273
  4. Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med. 2005;142:821–831
  5. Enriquez AD, Campbell MS, Reddy KR. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis. Aliment Pharmacol Ther. 2007;26:383–391
  6. Veenstra DL, Sullivan SD, Clarke L, et al. Cost-effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2007;25:963–977
  7. Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2008;26:937–949
  8. Toy M, Veldhuijzen IK, de Man RA, et al. Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatology. 2009;50:743–751
  9. Mostert MC, Richardus JH, de Man RA. Referral of chronic hepatitis B patients from primary to specialist care: making a simple guideline work. J Hepatol. 2004;41:1026–1030
  10. Cohen C, Evans AA, London WT, et al. Underestimation of chronic hepatitis B virus infection in the United States of America. J Viral Hepat. 2008;15:12–13
  11. CDC. Screening for chronic hepatitis B among Asian/Pacific Islander populations—New York City, 2005. MMWR Morb Mortal Wkly Rep. 2006;55:505–509
  12. Marschall T, Kretzschmar M, Mangen MJ, et al. High impact of migration on the prevalence of chronic hepatitis B in The Netherlands. Eur J Gastroenterol Hepatol. 2008;20:1214–1225
  13. Toy M, Veldhuijzen IK, Mostert MC, et al. Transmission routes of hepatitis B virus infection in chronic hepatitis B patients in The Netherlands. J Med Virol. 2008;80:399–404
  14. Koedijk FD, op de Coul EL, Boot HJ, et al. [Hepatitis B surveillance in the Netherlands, 2002–2005: acute infection is mainly via sexual contact while chronic infection is via vertical transmission through mothers from endemic regions]. Ned Tijdschr Geneeskd. 2007;151:2389–2394
  15. Hutton DW, Tan D, So SK, et al. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med. 2007;147:460–469
  16. World Health Organization. Hepatitis B. 2002 http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdfAccessed March 1, 2009
  17. Bouma M, van Geldrop WJ, Numans ME, et al. [Summary of the practice guideline “Viral hepatitis and other liver diseases” (second revision) from the Dutch College of General Practitioners]. Ned Tijdschr Geneeskd. 2008;152:2662–2666
  18. Veldhuijzen IK, Mostert MC, Niesters HG, et al. Accuracy of a referral guideline for patients with chronic hepatitis B in primary care to select patients eligible for evaluation by a specialist. Gut. 2007;56:1027–1028
  19. Buster EH, van Erpecum KJ, Schalm SW, et al. Treatment of chronic hepatitis B virus infection—Dutch national guidelines. Neth J Med. 2008;66:292–306
  20. van der Klis FRM, Mollema L, Berbers GAM, et al. Second national serum bank for population-based seroprevalence studies in The Netherlands. Neth J Med. 2009;67:301–308
  21. Preventicon. Annual report 2006. (in Dutch). Utrecht Philadelphia, PA: Lipincott; 2007;
  22. Kanwal F, Farid M, Martin P, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol. 2006;101:2076–2089
  23. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335–352
  24. Bortolotti F, Guido M, Bartolacci S, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology. 2006;43:556–562
  25. Iorio R, Giannattasio A, Cirillo F, et al. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis. 2007;45:943–949
  26. Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002;97:2886–2895
  27. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study (The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP)). J Hepatol. 1994;21:656–666
  28. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B (The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis). Hepatology. 1995;21:77–82
  29. Nederlandse Transplantatie Stichting. www.transplant.orgAccessed November 1, 2008
  30. European Liver Transplant Registry. www.eltr.orgAccessed November 1, 2008
  31. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–1010
  32. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–1020
  33. Colonno RJ, Rose RE, Pokornowski K, et al. Four-year assessment of entecavir resistance in nucleoside naïve and lamivudine refractory patients. J Hepatol. 2007;46:S294
  34. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531
  35. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49:1503–1514
  36. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–242
  37. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539
  38. Shouval D, Lai CL, Chang TT, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol. 2009;50:289–295
  39. Baaten GG, Sonder GJ, Dukers NH, et al. Population-based study on the seroprevalence of hepatitis A, B, and C virus infection in Amsterdam, 2004. J Med Virol. 2007;79:1802–1810
  40. Veldhuijzen IK, Conyn-Van Spaendonck MAE, Dorigo-Zetsma JW. Seroprevalence of hepatitis B and C in the Dutch population. Infectieziekten Bulletin. 1999;10:182–184
  41. Dutch Health Care Authority (NZa). http://www.nza.nl/13755/14184/CI-1094_Tarieflijst_instell2.pdfAccessed January 15, 2009
  42. Oostenbrink JB, Rutten FF. Cost assessment and price setting of inpatient care in The Netherlands (The DBC case-mix system). Health Care Manag Sci. 2006;9:287–294
  43. Dutch Health Care Insurance Board (CVZ). http://www.medicijnkosten.nl/Accessed January 15, 2009
  44. Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. 2008;11:527–538
  45. Niessen LW, Grijseels E, Koopmanschap M, et al. Economic analysis for clinical practice—the case of 31 national consensus guidelines in The Netherlands. J Eval Clin Pract. 2007;13:68–78
  46. Robotin MC, Kansil M, Howard K, et al. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol. 2009;50:990–998
  47. Tong MJ, Hsien C, Hsu L, et al. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology. 2008;48:1070–1078
  48. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582–592
  49. Veenstra DL, Spackman DE, Di Bisceglie A, et al. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2008;27:1240–1252
  50. Robinson T, Bullen C, Humphries W, et al. The New Zealand Hepatitis B Screening Programme: screening coverage and prevalence of chronic hepatitis B infection. N Z Med J. 2005;118:U1345
  51. Wilson JGM, Junger G. Prinicples and practice of screening for disease. Geneva: World Health Organization; 1968;
  52. Shamliyan TA, Macdonald R, Shaukat A, et al. Antiviral therapy for adults with chronic hepatitis b: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med. 2009;150:111–124

 Conflicts of interest The authors disclose the following: Prof. S.W. Schalm has received research grants and speaker's fees from GlaxoSmithKline and Bristol-Myers Squibb, respectively. The remaining authors disclose no conflicts.

 Funding Supported by EU grant (LSHM-CT-2004-503359) VIRGIL to Erasmus MC and by an unrestricted grant from the Foundation for Liver Research to Erasmus MC.

PII: S0016-5085(09)01936-2

doi: 10.1053/j.gastro.2009.10.039

Gastroenterology
Volume 138, Issue 2 , Pages 522-530 , February 2010

Article Tools

* Image Usage & Resolution